The Clorox Company $CLX Shares Acquired by Boston Trust Walden Corp

Boston Trust Walden Corp boosted its holdings in The Clorox Company (NYSE:CLX) by 7.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 307,150 shares of the company’s stock after purchasing an additional 21,915 shares during the quarter. Boston Trust Walden Corp owned approximately 0.25% of Clorox worth $36,880,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the business. American National Bank & Trust boosted its position in shares of Clorox by 69.5% in the second quarter. American National Bank & Trust now owns 217 shares of the company’s stock worth $26,000 after acquiring an additional 89 shares during the last quarter. Ransom Advisory Ltd acquired a new position in shares of Clorox in the 1st quarter valued at $35,000. GW&K Investment Management LLC grew its stake in shares of Clorox by 239.1% during the 1st quarter. GW&K Investment Management LLC now owns 295 shares of the company’s stock valued at $43,000 after buying an additional 208 shares during the period. Ameritas Advisory Services LLC acquired a new stake in shares of Clorox during the 2nd quarter worth $48,000. Finally, Roble Belko & Company Inc increased its holdings in shares of Clorox by 140.7% during the 1st quarter. Roble Belko & Company Inc now owns 361 shares of the company’s stock worth $53,000 after buying an additional 211 shares during the last quarter. 78.53% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Clorox

In other news, COO Eric H. Reynolds sold 15,041 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the completion of the sale, the chief operating officer owned 54,221 shares of the company’s stock, valued at approximately $6,711,475.38. This trade represents a 21.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.63% of the company’s stock.

Clorox Price Performance

CLX opened at $119.50 on Wednesday. The Clorox Company has a twelve month low of $116.53 and a twelve month high of $171.37. The firm has a market cap of $14.55 billion, a price-to-earnings ratio of 18.33, a PEG ratio of 1.00 and a beta of 0.52. The company has a current ratio of 0.84, a quick ratio of 0.57 and a debt-to-equity ratio of 5.15. The company has a fifty day simple moving average of $122.02 and a 200 day simple moving average of $128.33.

Clorox (NYSE:CLX) last posted its quarterly earnings data on Thursday, July 31st. The company reported $2.87 earnings per share for the quarter, beating analysts’ consensus estimates of $2.24 by $0.63. Clorox had a net margin of 11.40% and a return on equity of 377.86%. The company had revenue of $1.99 billion during the quarter, compared to analysts’ expectations of $1.94 billion. During the same period in the prior year, the company posted $1.82 EPS. The firm’s revenue for the quarter was up 4.5% on a year-over-year basis. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. Equities research analysts expect that The Clorox Company will post 7.15 EPS for the current fiscal year.

Clorox Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, November 6th. Shareholders of record on Wednesday, October 22nd will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date of this dividend is Wednesday, October 22nd. Clorox’s dividend payout ratio is presently 76.07%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. UBS Group lowered their price target on Clorox from $134.00 to $128.00 and set a “neutral” rating for the company in a research report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Clorox from $135.00 to $128.00 and set a “hold” rating for the company in a research report on Monday. Jefferies Financial Group reduced their price target on shares of Clorox from $167.00 to $145.00 and set a “buy” rating on the stock in a research report on Thursday, June 26th. Bank of America decreased their price objective on shares of Clorox from $135.00 to $125.00 and set a “neutral” rating for the company in a research note on Wednesday, October 8th. Finally, TD Cowen cut their target price on shares of Clorox from $120.00 to $117.00 and set a “hold” rating on the stock in a research note on Wednesday, October 1st. One equities research analyst has rated the stock with a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus price target of $131.64.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.